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Abstract
Objective: To determine the inflammatory analytes that predict clinical pro-
gression and evaluate their performance against biomarkers of neurodegenera-
tion. Methods: A longitudinal study of MCI-AD patients in a Discovery cohort
over 15 months, with replication in the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) MCI cohort over 36 months. Fifty-three inflammatory analytes
were measured in the CSF and plasma with a RBM multiplex analyte platform.
Inflammatory analytes that predict clinical progression on Clinical Dementia
Rating Scale-Sum of Boxes (CDR-SB) and Mini Mental State Exam scores were
assessed in multivariate regression models. To provide context, key analyte
results in ADNI were compared against biomarkers of neurodegeneration, hip-
pocampal volume, and CSF neurofilament light (NfL), in receiver operating
characteristic (ROC) analyses evaluating highest quartile of CDR-SB change
over two years (≥3 points). Results: Cerebrospinal fluid inflammatory analytes
in relation to cognitive decline were best described by gene ontology terms, nat-
ural killer cell chemotaxis, and endothelial cell apoptotic process and in plasma,
extracellular matrix organization, blood coagulation, and fibrin clot formation
described the analytes. CSF CCL2 was most robust in predicting rate of cogni-
tive change and analytes that correlated to CCL2 suggest IL-10 pathway dysreg-
ulation. The ROC curves for ≥3 points change in CDR-SB over 2 years when
comparing baseline hippocampal volume, CSF NfL, and CCL2 were not signifi-
cantly different. Interpretation: Baseline levels of immune cell chemotactic
cytokine CCL2 in the CSF and IL-10 pathway dysregulation impact longitudinal
cognitive and functional decline in MCI-AD. CCL2’s utility appears comparable
to biomarkers of neurodegeneration in predicting rapid decline.
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Alzheimer’s disease (AD), which often presents early in
its course with episodic memory loss, is the most com-
mon cause of dementia. It is increasingly recognized that
there is considerable heterogeneity in AD phenotype and
clinical trajectories.1,2 Molecular factors that underpin
this heterogeneity, however, remain ill-defined. Increasing
evidence suggests that inflammatory pathways may
regulate AD progression.3–6 There has been a significant
increase in interest for evaluating inflammatory changes
in clinical AD with several studies reporting inflamma-
tion related changes in AD clinical cohorts over the last
5 years.7–10
There are also some key gaps in clarifying the role of
inflammation across multiple clinical studies. These gaps
include determining which specific peripheral and central
immunological analytes and related pathways impact rate
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of cognitive decline in human AD. There have been chal-
lenges in interpreting these results against longitudinal
rate of disease progression. Often, the directionality and
magnitude of these associations on clinical outcomes also
often differ, likely due to the use of a small number of
measured inflammatory analytes, varied methodologies,
and different stages of disease.6,11–16 In addition, it is
unclear how any of these analytes compare with other
widely used biomarkers of neurodegeneration, MRI hip-
pocampal volume, and the novel biomarker neurofilament
light (NfL) on disease progression.
To help identify inflammatory pathways or networks of
inflammatory analytes pertinent to cognitive decline in
AD, it is crucial to develop approaches that evaluate mul-
tiple analytes concomitantly and interrogate their clinical
significance when expressed together. We therefore have
taken a systematic approach to answer these gaps in mild
cognitive impairment (MCI) with AD consistent CSF
biomarkers, (MCI-AD) in whom the nature of inflamma-
tory changes were characterized by the same multiplex
panel of inflammatory analytes in the both the CSF and
plasma. After evaluation in our Discovery cohort, we vali-
dated the results among MCI patients in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) cohort.
Using bioinformatics and classical statistical tools, we
determined (1) the key inflammatory analytes at baseline
that best predict future cognitive decline, (2) the biologi-
cal pathways most likely disrupted in relation to the
above analytes and (3) how they compare to neurodegen-
eration biomarkers, MRI hippocampal volume, and cere-
brospinal fluid (CSF) NfL. We tested the hypotheses that
(1) a proinflammatory analyte profile at baseline would
relate to a faster rate of longitudinal clinical progression
in the MCI-AD and (2) key inflammatory analytes have
at least comparable utility to neurodegeneration biomark-
ers in predicting future cognitive decline.
Materials and Methods
Discovery cohort
Forty-eight MCI-AD patients at baseline in whom the diag-
nosis of MCI-AD with CSF Ab42 and p-tau181 levels consis-
tent with a diagnosis of AD and consensus evaluation of
two neurologists and a neuropsychologist the details of
which have been published previously.17,18 The study was
approved by the Cleveland Clinic Institutional Review
Board. Eight patients did not complete the longitudinal
evaluations due to nonmedical reasons by their personal
choice. The ADmark Alzheimer’s evaluation uses sand-
wich Enzyme Linked Immunosorbant Assay(ELISA) kits
[Innotest b-amyloid[1-42], Innotest hTAU-Ag, Innotest
Phospho-Tau[181P], Innogenetics, Ghent, Belgium]. APOE
status was determined by blood samples(10 ng per subject)
dispensed into 96-well plates for TaqMan allelic discrimi-
nation detection of single nucleotide polymorphisms that
discriminate the APOE alleles (rs429358, rs7412) (Life
Technologies). Table 1 provides data on the Discovery
cohort demographics. Inclusion, exclusion criteria are spec-
ified in Data S1. Additional clinical and environmental fac-
tors have been documented in Table S1 (Fig. 1).
Cognitive and functional measures
Mini–Mental State Examination (MMSE),19 and Clinical
Dementia Rating scale (CDR-SB)20 were conducted to
characterize the degree of their baseline cognitive and func-
tional deficit. Mini–Mental State Examination and CDR-SB
Table 1. Demographics of Discovery and ADNI cohorts.
Discovery (N = 48) ADNI ( N = 134)
P-valueN Statistics N Statistics
Age at enrollment 48 68.1  7.3 134 74.9  7.2 <0.001a1
Gender 48 134 0.23c
Male 28 (58.3) 91 (67.9)
Female 20 (41.7) 43 (32.1)
Years of education 48 16.0 [12.5, 18.0] 134 16.0 [14.0, 18.0] 0.27b
APOE e4positive 48 37 (77.1) 134 72 (53.7) 0.005c
MMSE - baseline 48 24.8  3.1 134 26.9  1.8 <0.001a2
CDR-SB - baseline 48 2.1  1.2 134 1.5  0.89 0.002a2
CSF AB42, pg/mL 48 305.9 [216.1, 367.1] 134 144.5 [129.0, 171.0]
CSF t-tau, pg/mL 48 454.3 [335.2, 771.3] 134 90.6 [67.8, 134.0]
CSF p-tau, pg/mL 48 79.6 [59.3, 104.6] 134 35.7 [23.0, 45.8]
Statistics presented as Mean  SD, Median [P25, P75], N (column%).
P-values: a1 = t-test, a2 = Satterthwaite t-test, b = Wilcoxon Rank Sum test, c = Pearson’s chi-square test, d = Fisher’s Exact test.
P-value < 0.05 is noted in bold.
CDR-SB, Clinical dementia rating scale-sum of boxes; MMSE, Mini mental state exam.
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scores were also evaluated longitudinally to evaluate cogni-
tive change at 9 and 15 months from baseline evaluations.
Inflammatory biomarkers
The biomarker analysis protocol used in this study has been
previously described (18). In brief, CSF and plasma were col-
lected and analyzed by an independent laboratory via the val-
idated RBM Multi-Analyte Profile (MAP) platform from
Myriad Genetics (Salt Lake City, UT). Samples were evalu-
ated for levels of 86 analytes using a custom MAP:
HumanMAPv2.0 + IL1 and 16 using a Luminex platform.
Validation has been performed as defined by the Clinical and
Laboratory Standards Institute and is therefore replicable
across multiple runs. Cerebrospinal fluid and plasma samples
were collected contemporaneously. Only those analytes with
at least 50% response rate above the limit of detection in the
Discovery cohort were included for further analysis.
ADNI validation cohort
Alzheimer’s Disease Neuroimaging Initiative is a longitu-
dinal multicenter study designed to develop clinical,
imaging, genetic, and biochemical biomarkers for the
early detection and tracking of AD. Alzheimer’s Disease
Neuroimaging Initiative was launched by the National
Institute of Aging and is a multicenter project with addi-
tional support from private pharmaceutical companies,
and nonprofit organizations. ADNI 1 eligibility criteria
are described in the ADNI 1 protocol http://adni.loni.
usc.edu/methods/documents/.
The demographics at baseline among the subset of all
134 ADNI MCI participants who had CSF and plasma mul-
tiplex data were used in the validation analysis are shown
in Table 1. Longitudinal cognitive evaluations in the ADNI
cohort documented at 12, 24, and 36 months were
included in the analysis. AD CSF biomarker data were
downloaded from http://adni.loni.usc.edu/ in which the
CSF Ab1-42, t-tau, and p-tau181 concentration data were
generated using the Research Use Only (RUO) INNOBIA
AlzBio3 immunoassay (Fujirebio, Belgium). Median values
for each subject were used in the analysis. Amyloid-positiv-
ity based on a published, autopsy-confirmed cutoff value
(<192 pg/mL) were used in a subgroup analysis to define
MCI-AD21,22 of which there were 106 participants (see Data
S1). Cerebrospinal fluid samples were measured for levels
of 159 analytes using the RBM DiscoveryMAP v.1.0 panel.
The RBM HumanMAP v.2.0 used in the Discovery cohort
is a subset of the RBM DiscoveryMAP v.1.0 and uses a
Luminex platform with the same quality control and
thresholding process used in ADNI dataset and are compa-
rable. CSF NFL was measured using a sandwich ELISA
method and provided as pg/ml (NF-light ELISA kit,
UmanDiagnostics AB, Umea, Sweden), as described previ-
ously. The lower limit of quantification for this assay was
50 ng/L.23 Subject data quality was checked.
Bioinformatics and statistical analysis
Ontology analysis and network analysis to
identify inflammatory analytes
Our final comprehensive list of 53 candidate inflammatory
analytes (from 86 analytes in RBM MAP platform in the Dis-
covery cohort) is provided in Table 2 and has been previously
described18 and rationale describing selection is in Data S1.
Subgroup searching for analyte synergistic
relationships
Univariate analyses often fail in validation as they are
trained on the specific patient dataset of the discovery
Figure 1. Methodological overview.
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project, and average the heterogeneities present, while the
validation cohort may have differences in the levels of
individual analytes from multiple environmental factors.
Network biology methods, specifically network based bio-
marker models, can effectively integrate heterogeneities at
the patient level and provide robust validation across
cohorts. In order to evaluate analyte levels that show
higher correlation when considered together (synergistic
relationship) rather than individual analyte correlation by
univariate analysis alone, we performed an exhaustive
search to find analyte subgroups whose aggregate levels
maximally correlated with cognitive change mea-
sures.18,24,25 Hypothesis 1 (H1) tested how likely we were
to see greater or equal correlation with random analyte
subgroups by sampling 10,000 random analyte subgroups
from among all analytes that met the 50% detection
threshold and computing the correlation values. Hypothe-
sis 2 (H2) tested how likely we were to randomly observe
greater or equal correlation between the aggregate activity
of an analyte subgroup and a response marker by per-
muting the values of each response marker 10,000 times
and computing the correlation values to the aggregate
analyte levels. P-values were estimated as the proportion
of randomized responses with equal or greater correlation
to aggregate analyte levels than the actual response.
Functional pathway analysis on analytes of
interest
The analytes of significance identified as being shared
across both the Discovery and ADNI cohorts in at least
one time point in the analyte subgroup search above were
entered into STRING: functional protein association net-
works for pathway enrichment analysis.26 The most sig-
nificant GO terms related to biological process identified
in STRING (P < 0.05) were summarized into nonredun-
dant hierarchical terms by their semantic similarity via
ReviGO,27 using SimRel28 as the clustering algorithm with
a similarity measure of 0.70, with the whole Uniprot
database providing GO term sizes and reported in appro-
priate plots. The Reactome pathway database was used in
enrichment analysis to identify targeted analyte pathways
of interest in any secondary analysis.29
Structural MRI acquisition and processing
ADNI 1.5-T MRI scans from MCI subjects performed at
baseline were processed using cross-sectional FreeSurfer
(version 5.1.0, default parameters).30 The processing
included conformation to isotropic cubic mm resolution,
bias field correction, segmentation of the hippocampi
Table 2. List of inflammatory analytes analyzed in relation to longitudinal cognitive change.
RBM Name Gene RBM Name Gene
1. Alpha-1-Antitrypsin (AAT) SERPINA1 27. Interleukin-12 Subunit p40 IL12B
2. Alpha-2-Macroglobulin A2M 28. Interleukin-12 Subunit p70 IL12P70
3. Apolipoprotein A-I APOA1 29. Interleukin-15 IL15
4. Beta-2-Microglobulin B2M 30. Interleukin-17 IL17A
5. Brain-Derived Neurotrophic Factor BDNF 31. Interleukin-18 IL18
6. Complement C3 C3 32. Interleukin-8 CXCL8
7. C-Reactive Protein CRP 33. Interleukin-23 IL23A
8. Eotaxin-1 CCL11 34. Macrophage Inflammatory Protein-1 alpha CCL3
9. Fibrinogen FGA 35. Macrophage Inflammatory Protein-1 beta CCL4
10. Factor VII F7 36. Matrix Metalloproteinase-3 MMP3
11. Ferritin FTH1 37. Matrix Metalloproteinase-9 MMP9
12. Granulocyte-Macrophage Colony-Stimulating Factor CSF2 38. Monocyte Chemotactic Protein 1 CCL2
13. Granulocyte Colony-Stimulating Factor CSF3 39. Matrix Metalloproteinase-2 MMP2
14. Haptoglobin HP 40. Myeloperoxidase MPO
15. Intercellular Adhesion Molecule 1 ICAM1 41. Neuron-Specific Enolase (NSE) ENO2
16. Interferon gamma IFNG 42. Plasminogen Activator Inhibitor 1 (PAI-1) SERPINE1
17. Interleukin-1 alpha IL1A 43. Serotransferrin TF
18. Interleukin-1 beta IL1B 44. Stem Cell Factor SCF
19. Interleukin-1 receptor antagonist IL1RN 45. T-Cell-Specific Protein RANTES CCL5
20. Interleukin-2 IL2 46. Tissue Inhibitor of Metalloproteinases 1 TIMP1
21. Interleukin-3 IL3 47. Tumor Necrosis Factor alpha TNF
22. Interleukin-4 IL4 48. Tumor Necrosis Factor beta LTA
23. Interleukin-5 IL5 49. Tumor necrosis Factor Receptor 2 TNFRSF1B
24. Interleukin-6 IL6 50. Vascular Cell Adhesion Molecule-1 VCAM1
25. Interleukin-7 IL7 51. Vascular Endothelial Growth Factor VEGFA
26. Interleukin-10 IL10 52. Vitamin D-Binding Protein GC
53. von Willebrand Factor VWF
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from which the bilateral hippocampal volume was com-
puted, and estimation of total intracranial volume.31 The
baseline hippocampal volume was corrected for head size
by division by the intra cranial volume.
Clustering analysis
To further provide biological context to the key shared
analyte robustly identified across both ADNI and Discov-
ery cohorts it was subjected to consensus clustering, an
unsupervised class discovery approach to identify co-oc-
curring analytes.32 Using the quantitative values of the
analytes, the number and possible memberships to clus-
ters were found for each cluster. Cluster size for each
group was fixed where relative increase in consensus was
observed to have no appreciable increase. The analyte
groups were tested for enrichment in pathways using
ClusterProfiler tool using the Reactome Pathway Data-
base33 and the top five enriched Reactome pathways were
interpreted.
Statistical analysis
Given the limited number of conversion events (dementia
onset or highest quartile of CDR-SB change) during inter-
mediate follow-ups (9 and 12 months) in both the Dis-
covery and ADNI MCI cohorts, neither Cox proportional
hazards model nor a time-dependent receiver operating
characteristic (ROC) were found to be adequate for the
data. With the Discovery sample size, and conservatively
choosing a Bonferroni corrected significance level of 0.005
to allow for up to 10 key analytes to be compared, there
would be 80% power to detect correlations between ana-
lytes and changes in cognitive measures that exceed 0.5.
Key inflammatory analytes shared between both cohorts,
curated from the synergistic subgroup analysis described
previously and used for functional pathway analysis, were
next evaluated in predicting cognitive change after adjust-
ing for age, sex, baseline MMSE, and APOEe4 status (pre-
sent vs. absent). With five adjustment factors, the
Discovery cohort models included no more than three
biomarkers concurrently to maintain a 5 to 1 ratio of
observations to variables as noted in prior statistical liter-
ature.34 Two statistical approaches for variable selection
were used. First, a best subset regression analysis was used
to identify two to three biomarkers that best predicted
outcome. In this approach, the third biomarker solution
was used only if including the third biomarker increased
the R2 by at least 1%. As an alternative, penalized regres-
sion using LASSO regression was performed, using Akaike
information criterion (AIC) as the stopping rule. In gen-
eral, as the LASSO approach was very conservative the
best subset results are presented.
A log (base 2) transformation allowed Pearson correla-
tions to be fit for exploratory univariate analysis. Along
with estimates of correlation, 95% confidence intervals
and p-values with false discovery rate (FDR) adjustment
were calculated. Normality of biomarkers was evaluated
using Shapiro–Wilk tests and graphical methods. Sensitiv-
ity analyses were also performed to evaluate the robust-
ness of the key analytes of significance. All analyses were
performed at each time point using the patients with
available cognitive change measures at that point. Sepa-
rate analyses were performed at each time point because
we hypothesized that the biomarkers related to cognitive
change may change over time and the sample size did not
allow for modeling of interactions to capture these com-
plex relationships. We chose not to impute change mea-
sures for missing responses as doing so would not
improve the information available.35
Classical ROC analyses were performed for subjects
only in the ADNI cohort, to explore if key CSF inflam-
matory analytes were comparable to hippocampal volume
and CSF NfL in their clinical utility as all three data were
available. Analyses were performed for a base model with
above three variables alone and for an adjusted model
that included age, sex, education years, APOEe4 status,
and CSF Ab/ptau ratio. The area under the ROC curve
(AUC) was maximized in these analyses. In this setting,
the AUC measures the intrinsic ability of the analytes to
discriminate between subjects who progress ≥ 3 CDR-SB
points, the highest quartile CDR-SB change in the ADNI
cohorts for two year follow-up. Analysis was performed
using SAS software (version 9.4), R software (version 3.x;
Vienna, Austria), and SPSS (Version 22.0. Armonk, NY:
IBM Corp) an overall significance level of 0.05 was
assumed.
Results
Subject demographics of the Discovery and ADNI cohorts
are presented in Table 1.
Analyte subgroup analysis for synergistic
relationships in discovery and ADNI cohorts
Analyte levels that show higher correlation when consid-
ered together rather than the individual component ana-
lytes (synergistic analyte analysis) are reported in Tables
S3 and S4 and Figures 2A and 3A. The Discovery
cohort had a similar number of analytes compared with
the ADNI cohort that relate to cognitive changes in the
CSF and in plasma. The analytes noted in relation to
CDR-SB change in a consistent direction among both
cohorts in the CSF included CCL2, CCL4, and FGA,
while in plasma the shared analytes in a consistent
1230 ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Inflammatory Analytes Predicting rapid AD Progression J. A. Pillai et al.
direction included APOA1, BDNF, and vWF. Among
both cohorts, the CSF analytes noted in relation to
MMSE change in a consistent direction across both
cohorts included AAT, MMP3, and CRP, while in
plasma MMP2, CXCL8, A2M, and Factor VII were best
correlated to MMSE change consistently across both
cohorts (Figs. 2A and 3A).
Functional pathway analysis
The analytes that significantly correlated to at least one
time point of longitudinal follow-up in both Discovery
and ADNI cohorts in a consistent direction within the
subgroup synergistic analysis were ranked as the most
robust for functional pathway analysis. These analytes
(for CSF: AAT, CCl2, CCL4, CRP, FGA, and MMP3 and
for plasma: A2M, APOA1, BDNF, CXCL8, F7 MMP2,
and vWF) were entered into STRING for functional path-
way enrichment analysis for CSF and plasma in different
runs. In the CSF, the largest clusters were most represen-
tative of natural killer cell chemotaxis, and regulation of
endothelial cell apoptotic process. While in the plasma,
clusters were representative of extracellular matrix organi-
zation, blood coagulation and fibrin clot formation, and
platelet degranulation (Figs. 2B and 3B).
Statistical analysis
Univariable analysis in CSF and plasma
In a complementary analysis, univariable Pearson correla-
tions after FDR correction in the Discovery cohort, only
CSF levels of CCL2 positively correlated to change in
CDR-SB scores at 15 months, and after adjusting for
covariates (age, sex, baseline cognitive score, APOE e4 sta-
tus), the association of CCL2 was still significant
(Table S4A).
Within the ADNI cohort, there were no significant CSF
analytes on univariable analysis that related to change in
CDR-SB or MMSE scores after adjusting for covariates.
In the plasma, only levels of MMP2 was negatively corre-
lated to change in MMSE scores at 24 months, and the
association was still significant after adjusting for covari-
ates (age, sex, baseline cognitive score, APOE e4 status)
while applying the FDR correction (Table S5).
Multivariable models CSF and plasma
Across both cohorts, CSF CCL2 was the most robustly
selected parameter being chosen in 9 out of 10 models,
and was significant at the 0.05 level in five models. MMP3
was chosen in four models and met significance threshold
Figure 2. (A) Heat map denoting significant analytes from ADNI and Discovery datasets in the CSF from the subgroup synergistic analysis
correlated to cognitive change (CDR-SB or MMSE) for 9,12,15,24, and 36 months. Red: positive correlation, Blue: negative correlation, Magenta:
has representation in both positive and negative correlation network of analytes. Given that higher CDR-SB is worse cognition and function while
lower MMSE is worse cognition, a positive correlation in CDR-SB relates to worsening cognition while the negative MMSE correlations relates to
worsening cognition. (B) Abundance of Gene Ontology (GO) terms related to biological processes that enrich for key shared analytes between
ADNI and Discovery datasets in the CSF in relation to cognitive change (CDR-SB or MMSE). Analytes included: AAT, CCl2, CCL4, CRP, FGA, and
MMP3. GO term most representative of each cluster is noted.
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in three models. CSF CCL4 selected in four models, was
significant in only two models. In the Discovery cohort,
the multivariable models explained 27–42% of the vari-
ability in cognitive change, while in ADNI, only 13–19%
of the variability in cognitive change was explained with
these models (Table 3). Additional sensitivity analysis to
evaluate the role of extreme measures using a rank based
analysis noted CSF CCL2 as significant in all prior models,
MMP3 was no longer significantly related to CDR-SB
change at 15 months.
In the plasma, a clear pattern replicating the findings
between Discovery and ADNI data does not appear to be
present in the multivariable models (Table 4). Across
both cohorts, there were no analytes with correlations in
opposing directions to the same cognitive change scores
when correlations exceeded +/- 0.2 in the univariable
models in CSF and plasma. In the multivariable models
with MMSE, plasma BDNF and MMP2 differ in correla-
tion direction between cohorts. Plasma MMP2 changes
correlation direction within the ADNI cohort over time,
indicating the instability of this effect when cognitive
change is characterized by MMSE.
Inflammatory diseases and NSAID intake
No difference was noted in the analytes of significance
when adjusted for current NSAID intake or when consid-
ering inflammatory diseases in clinical history within the
Discovery cohort. Adjusting for individual CSF/plasma
albumin ratio again noted no impact on key analytes of
significance (analyses not presented).
Comparing inflammatory analytes in ADNI versus the
Discovery cohort
The inflammatory analyte correlations to cognitive change
within the Discovery cohort were larger than in the ADNI
dataset (Tables S4 and S5). The analytes that were identified
as correlating to at least one longitudinal cognitive measure
across both datasets could be further validated after
accounting for multiple covariates in the multivariable
models (Tables 3 and 4). CSF CCL2 was identified as a key
analyte shared between cohorts in relation to CDR-SB
change. In a subgroup analyses of ADNI MCI participants
with CSF Ab42 < 192 pg/mL (and additionally CSF t-tau/
Figure 3. (A) Heat map denoting significant analytes from ADNI and Discovery datasets in the plasma from the subgroup synergistic analysis
correlated to cognitive change (CDR-SB or MMSE) for 9,12,15,24, and 36 months. Red: positive correlation, Blue: negative correlation, Magenta:
has representation in both positive and negative correlation network of analytes. 3B: Abundance of Gene Ontology (GO) terms related to
biological processes that enrich for key shared analytes between ADNI and Discovery datasets in the plasma in relation to cognitive change.
Analytes chosen for their consistency of response included: A2M, APOA1, BDNF, CXCL8, F7, MMP2, and vWF. GO term most representative of
each cluster is noted.
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Ab42> 0.4), the direction of correlation between CCL2 and
CDR-SB change on univariable analysis was consistent
between 24 and 36 months and met significance threshold
at 36 months (Table S6). From the multivariable analysis, a
doubling of baseline CSF CCL2 levels in the Discovery
cohort predicted a 2.8 point estimated increase in CDR-SB
change at 15 months. A similar doubling in the ADNI MCI
cohort predicted a 0.9 point increase of CDR-SB over
24 months and 1.4 point over 36 months, after accounting
for age, sex, education, APOE e4 status, and baseline cogni-
tive scores (Table 3, Fig. 4).
To provide a biological context to the role for CCL2,
we next explored the clustering of CCL2 to other inflam-
matory analytes. We note that in the Discovery cohort
Table 3. CSF biomarkers of CDR-SB and MMSE change are shown for both cohorts at specified time points, after adjustment for age, sex, APOE
status and education.
Time
CDR-SB change MMSE change
Factor Estimate (95% CI) P-value Factor Estimate (95% CI) P-value
Discovery cohort
9 months CCL2 1.23 (0.24, 2.22) 0.016 AAT 1.50 (0.85, 3.85) 0.20
MMP3 0.97 (1.64, 0.29) 0.006 CCL2 1.54 (4.09, 1.02) 0.23
MMP3 2.05 (0.32, 3.78) 0.022
15 months FGA 0.27 (0.73, 0.20) 0.25 AAT 1.53 (1.24, 4.30) 0.27
CCL2 2.82 (1.30, 4.34) <0.001 CCL2 2.36 (5.47, 0.76) 0.13
MMP3 0.94 (1.82, 0.05) 0.039 CCL4 1.48 (0.15, 3.12) 0.073
ADNI Cohort
12 months AAT 0.37 (0.10, 0.85) 0.12 CCL2 1.45 (2.54, 0.36) 0.009
CCL4 0.30 (0.03, 0.63) 0.071 FGA 0.49 (0.13, 0.86) 0.008
FGA 0.23 (0.40, 0.05) 0.011
24 months CCL2 0.86 (0.04, 1.75) 0.062 CCL2 1.46 (3.19, 0.26) 0.096
CCL5 0.41 (0.02, 0.79) 0.041 CCL5 0.43 (1.18, 0.31) 0.25
CRP 0.26 (0.65, 0.13) 0.20
36 Months CCL2 1.43 (0.13, 2.73) 0.031 CCL2 2.87 (5.16, 0.58) 0.015
CCL4 0.76 (0.01, 1.52) 0.047 CCL4 1.36 (2.71, 0.00) 0.050
MMP3 0.53 (1.25, 0.19) 0.15 CCL5 0.74 (0.50, 1.98) 0.24
P-value < 0.05 is noted in bold
Table 4. Plasma biomarkers of CDR-SB and MMSE change are shown for both cohorts at specified time points, after adjustment for age, sex,
APOE status and education.
Time
CDR-SB Change MMSE Change
Factor Estimate (95% CI) P-value Factor Estimate (95% CI) P-value
Discovery cohort
9 months CXCL8 0.37 (0.39, 1.12) 0.33 A2M 4.24 (7.67, 0.81) 0.017
F7 1.19 (2.04, 0.34) 0.007 F7 1.97 (3.81, 0.13) 0.037
MMP2 0.70 (1.80, 0.41) 0.21 BDNF 0.28 (0.23, 0.79) 0.27
15 months CXCL8 1.75 (0.66, 2.84) 0.003 A2M 4.37 (8.62, 0.12) 0.044
APOA1 1.41 (3.75, 0.93) 0.23 F7 1.83 (4.26, 0.60) 0.13
F7 0.85 (2.14, 0.44) 0.19 MMP2 1.28(4.47, 1.92) 0.42
ADNI Cohort
12 months A2M 0.66 (0.06, 1.27) 0.032 CXCL8 1.03 (0.34, 1.71) 0.004
APOA1 0.28 (0.13, 0.69) 0.18 APOA1 0.61 (1.50, 0.28) 0.18
BDNF 0.24 (0.63, 0.15) 0.23
24 months APOA1 0.57 (0.08, 1.23) 0.086 APOA1 1.16 (2.35, 0.03) 0.057
BDNF 0.23 (0.05, 0.51) 0.10 MMP2 1.48 (0.88, 2.08) < 0.001
MMP2 0.56 (0.89, 0.22) 0.001
36 months A2M 1.73 (0.28, 3.74) 0.090 A2M 1.29 (3.91, 1.33) 0.33
MMP2 1.12 (0.19, 2.42) 0.093 APOA1 1.26 (3.13, 0.61) 0.18
P-value < 0.05 is noted in bold.
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CCL2 closely clusters with B2M, CXCL8, FGA, MMP2,
TIMP1, and VCAM1 in the CSF (Fig. S1) and plasma
CCL2 with BDNF, CCL4, CCL11, IL-18, PAI-1, and
VEGFA (Fig. S2). These analytes in the CSF and plasma
taken together are enriched in interleukin-10 (IL-10),
interleukin-4 (IL-4), and interleukin-13 (IL-13) signaling
pathways within the Reactome database (Tables S7 and
S8). In the ADNI cohort, CSF CCL2 did not significantly
cluster with other CSF analytes, while in the plasma,
CCL2 and correlated inflammatory plasma analytes were
enriched for the IL-10 signaling pathway (Fig. S3, Tables
S9). Summary statistics of these analytes are provided in
Data S1.
CSF versus plasma inflammatory analytes in predicting
future cognitive decline
Receiver operating characteristics based on the logistic
regression models determined the utility of CCL2 com-
pared with baseline CSF NfL and hippocampal volume to
predict the highest quartile of CDR-SB change over two
years in the ADNI cohort. The area under the curve
(AUC) of the adjusted model (age, sex, years of educa-
tion, APOE ɛ4 genotype, and CSF Ab1–42/p-tau) when it
included CSF CCL2 was 0.66, CSF NfL was 0.63, and hip-
pocampal volume was 0.69 (Fig. 5). The resulting AUCs
and overlapping 95% confidence intervals were statisti-
cally not different for these biomarkers (Table S10). A
nonsignificant correlation between CSF CCL2 and
baseline hippocampal volume, r = 0.15, P = 0.12 was
noted, while the correlation between CSF CCL2 and CSF
NfL was r = 0.19, P = 0.042.
Discussion
This study undertook an unbiased approach to evaluate
the role for inflammatory analytes on clinical progression
using a multi-analyte panel with well characterized MCI
patient cohorts and positive AD CSF biomarkers. Our
results across two cohorts of baseline CSF CCL2 predict-
ing rapid clinical decline lends credence to prior reports
of CCL2 impacting clinical progression in AD.13,36 In
addition as a novel finding, by carefully characterizing
chemokines that cluster closely with CCL2 in the CSF
and plasma using bioinformatics tools, we are able to
posit the relevance of IL-10 inflammatory pathway dys-
regulation as a correlate of clinical progression in MCI.
This result is consistent with our initial hypothesis that a
proinflammatory analyte profile at baseline would relate
to a faster rate of longitudinal clinical progression in the
MCI stage. Furthermore providing clinical context to
these results, we note that baseline measurements of the
cytokine CSF CCL2 has comparable discriminatory power
to neurodegeneration markers, CSF NfL and MRI hip-
pocampal volume, in predicting the highest quartile of
CDR-SB change over two years (≥3 CDR-SB) in MCI-
AD, but has limited correlation with either. Of note, 3
point CDR-SB change is over twice the change among
Figure 4. Histogram with normal distribution score of baseline CSF CCL2 levels, in relation to longitudinal CDR-SB change (in heat colors) and
average CDR-SB change of cohort at each time point (as a line in legend). Data from Discovery cohort (9 and 15 months), ADNI (12, 24 and
36 months).
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neuropathology confirmed AD patients in the National
Alzheimer’s Coordinating Center (NACC) database (Avg
0.9, SD 0.7, per year), when they met criteria for MCI at
initial visit.2
CCL2 (also known as monocyte chemoattractant pro-
tein-1, MCP-1) is among the key cytokines that recruit
monocytes to a site of inflammation. Infiltration of these
blood derived immune cells toward Ab plaque have been
studied.37,38 An increase in CSF CCL2 levels has been
linked to the transition from MCI to AD and a faster rate
of cognitive decline.13,36 Plasma CCL2 levels have been
observed to increase with the increasing severity of AD
dementia and associated with a 2-year rate of cognitive
decline in AD and MCI.36,39 Among asymptomatic nor-
mal aging individuals, longitudinal increases in plasma
CCL2 levels were associated with decline in memory40
and associated with increased long-term risk of stroke in
a meta-analysis of population studies.41
IL-10 Reactome pathway was enriched among the CSF
and plasma inflammatory analytes that CCL2 clustered
with in both ADNI and the Discovery cohorts, while IL-
13 and IL-4 pathways were enriched only in the Discovery
cohort. IL-10, IL-13, and IL-4 pathways are all associated
with anti-inflammatory changes noted in relation to inhi-
bition of autoimmunity and infections.42,43 The down-
stream proinflammatory factors in the IL-10 Reactome
pathway often suppressed by IL-10 were elevated. Given
the Lower Limit of Quantification (LLOQ) of the CSF IL-
10 assay only 3 of 48 patients in the Discovery cohort
had measurable IL-10 levels, limiting the assay’s utility in
estimating IL-10’s direct relevance in this context. In con-
trast to CCL2, the levels of MMPs were less consistently
correlated to cognitive change in both cohorts.
CCL2 compared to neurodegeneration
markers
To evaluate the utility of CSF CCL2 in predicting rapid
cognitive decline, we compared its effectiveness against
baseline CSF NfL and MRI hippocampal volume as they
both provide complementary information. Imaging mea-
sures like hippocampal volume represent the magnitude
of the neuropathologic damage accumulated over time,
unlike CSF markers like NfL that reflect its production/
clearance at one time point.44 CSF NfL has been noted to
correlate with rapid cognitive decline in MCI stage of AD
and is thought to be related to degeneration of large-cal-
iber axons.45 MRI measure of hippocampal volume is
accepted as an indicator of neurodegeneration in the A/T/
N classification.44 In the ROC analysis, CSF CCL2 had
nonsignificant differences from CSF NfL and hippocampal
volumes in predicting rapid cognitive decline in the
adjusted models that included covariates of clinical
importance. In the base model when these biomarkers
were considered without adjustment for covariates, CSF
CCL2 performed slightly better than CSF NfL (0.63 vs.
0.52), but was still within the 95% CI. The lack of corre-
lation between CCL2 and neurodegeneration biomarkers
suggests that they likely capture different pathobiological
signatures contributing to cognitive decline in MCI-AD.
Figure 5. Receiver operating characteristic analysis curves denoting CSF CCL2, CSF NfL, and hippocampal volume for rapid cognitive decline (≥ 3
CDR SB change over two years, highest quartile among subjects) from ADNI cohort. Base models of the three biomarkers alone and adjusted
models accounting for age, sex, years of education, APOE ɛ4 genotype, and CSF Ab1–42/p-tau.
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Inflammatory changes in the context of
neurodegeneration markers and clinical
progression
In our prior analysis, we had found TNFR2, SCF, and
Ferritin strongly correlated to neurodegeneration markers
and were expressed in the brain transcriptome.18 In the
current analysis, the above analytes were not significant in
predicting longitudinal cognitive change within three
years. The key inflammatory pathways are also likely to
be distinct in different stages of clinical AD and needs
further elucidation.
Even as migration of neutrophils toward amyloid pla-
ques are noted in some mouse models of AD,46 this is an
area that needs future investigation in MCI-AD patients
to determine if CCL2 determined immune cell migration
plays a role in impacting cognitive outcomes. The study
data also point to a wide variance in the inflammatory
analyte levels within patients at the same stage of MCI-
AD suggesting different degrees of inflammatory pathway
dysregulation. Taken together these data suggests a pro-
mise for targeted therapies against key inflammatory
pathways among patients in whom it is most dysregulated
to have a significant clinical outcome within the time
widows described in this study. The shared AUCs across
CSF CCL2 and neurodegeneration biomarkers in predict-
ing rapid cognitive change over two years but a lack of
significant correlation between them, suggest they could
play parallel roles in predicting disease progression.
Differences between Discovery and ADNI
cohorts
The current study noted key shared inflammatory analyte
correlations that were consistent between the Discovery
and ADNI cohorts. The Discovery cohort analytes had
larger correlation coefficients than ADNI in relation to
degree of cognitive decline. The correlations of cognitive/
functional change to CSF CCL2 are robust in the Discov-
ery data at 15 months, and get stronger over the 3-year
time of follow-up in the ADNI data. This may reflect a
slower progressing population in ADNI, or an earlier
stage of MCI in ADNI compared to Discovery cohort as
noted in Figure 4 and Table 1. The common analytes
meeting significance threshold in both ADNI and Discov-
ery cohort in the CSF was CCL2 and in the plasma was
CXCL8 (IL-8). CXCL8 was also the only analyte that clus-
tered with CCL2 in both the Discovery and ADNI cohort
plasma pathway analysis (Table S11). Additional differ-
ences between the two cohorts include differences in
duration of follow-up, AD biomarker levels at baseline
and patient recruitment characteristics: a memory clinic
sample of MCI subjects with notable cognitive concerns
in the Discovery cohort, versus a longitudinal MCI cohort
in ADNI with likely different medical and environmental
biases, as noted in the less robust correspondence in
plasma analytes compared to CSF between the two
cohorts. Despite these differences in data collection and
patient variables, key shared analytes were still identified
at baseline to have a longitudinally clinical impact across
both cohorts.
Strengths and limitations
The study’s strengths include a) concomitant measure-
ment of the same analytes in the CSF and plasma; b)
well-characterized patients including clinical variables (in-
flammation, vascular risk factors and medications), APOE
e4 status, and AD biomarkers, longitudinal assessment of
cognition and validation across two different cohorts with
potentially different recruitment biases; c) multiple inter-
nal and external validity checks to account for quality of
data and measurements, and d) going beyond single ana-
lyte associations to meaningfully assess multiple analytes
and narrow our focus to key activated biological processes
related to inflammation in AD with high confidence.
Despite these strengths, this study is not comprehensive
in determining the profile of inflammatory analytes as
some (e.g., YKL-40, sTREM2) were not analyzed. The
Discovery cohort and ADNI longitudinal cognitive mea-
surements do not have the same follow-up duration.
Additional inflammatory pathways could also be con-
tributing to cognitive outcomes than those posited fol-
lowing our analysis. We also have limited insight based
on baseline measures alone, as they themselves could be
dynamic and change longitudinally, contributing to varia-
tion in the temporal window of strongest cognitive out-
come in different stages of AD in both cohorts.
Future studies are needed to evaluate potential inflam-
matory analytes/pathways not covered in this analysis.
Our results pass a stringent multiple comparisons cutoff,
but it is possible that with weaker enrichment patterns
other analytes of significance may become more salient
with increased sample sizes. Lack of neuropathologic con-
firmation of diagnosis also limits our understanding of
the role for mixed pathology in MCI-AD.
Conclusion
We found that cognitive decline in MCI-AD was best pre-
dicted by CSF CCL2 and likely related to IL-10 pathway
dysregulation in the CSF and plasma. Baseline CSF CCL2
has comparable utility to CSF NfL and hippocampal vol-
ume in predicting rapid cognitive decline. Exploring the
triggers of this inflammatory response related to chemo-
taxis of immune cells and prospect of their modulation
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provides a potential therapeutic opportunity that is of
clinical interest in MCI-AD.
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